Sjögren's syndrome affects exocrine glands leading to a dry mouth and dry eyes. Dry eye manifestations can precede the diagnosis of Sjögren's syndrome by many years. Innumerous spontaneous and inducible Sjögren's syndrome models have been used to study the pathogenesis of Sjögren's syndrome. This review focuses on recent human data, ocular and extraglandular manifestations of animal models, what is known, what is still unknown and how we need to look, and their correlation correspondence to human disease.
INTRODUCTION
Sjögren's syndrome is characterized by symptoms of dry mouth and dry eye, secretory dysfunction of lacrimal and salivary glands, ocular surface staining, autoantibodies and focal lymphocyte infiltrate in salivary glands, and is about 10 times more frequent in women than in men. The autoimmune mechanism is the mostly accepted, and the primary cause is unknown [1] . The dry eye manifestations, Sjögren's syndrome or not Sjögren's syndrome-related, are the second most prevalent reason to visit an ophthalmologist. The hallmark of dry eye is corneal barrier disruption, clinically measured as increased uptake of fluorescent dyes such as fluorescein. For decades animal models have been used to better understand the physiopathology of Sjögren's syndrome. Countless rodent strains with or without interventions have been described in an attempt to identify tissues, cells and molecules involved in the pathogenesis and to figure out their interactions, possible causes and potential targets for therapy. However, very frequently, more attention is being given to the novelty of a rodent model, than to identify which strain better fits the most important parameters that define this syndrome [2] .
The three major questions regarding Sjögren's syndrome would benefit from research in an animal model or comparative analysis among those models that mimic better the disease. They are: the genetic and environmental causes and risk factors (etiology), the time-course of the disease (prognosis) and the efficient therapeutic approach (cure). The aim of the present review is to critically evaluate what is known about the relationship among the traditional and emerging animal models of Sjögren's syndrome and the characteristics that define Sjögren's syndrome, with special attention to ocular manifestations. Table 1 shows a summary of the models to be discussed [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 14 & ,15-18].
ADVANCES UNDERSTANDING SJÖ GREN'S SYNDROME MANIFESTATIONS AND APPROACH
A recent meta-analysis that filtered 21 articles from 1800, from the period between 1995 and 2013 showed an incidence of primary Sjögren's syndrome of seven cases per 100,000 people/year and the average age of the patients as 56 years' old [19 && ]. Clinical studies with large samples of patients with Sjögren's syndrome revealed that patients with extraglandular manifestations, including vasculitis and neuropathy have more severe ocular complications and higher risk of mortality [20 && ,21] . In addition, Sjögren's syndrome secondary to rheumatoid arthritis (RA) is a disease with distinct and more severe systemic characteristics when compared with primary Sjögren's syndrome [22] .
We have seen great advances in understanding the role of diagnostic tools to monitor and correlate inflammation in ocular, oral and extraglandular manifestations of Sjögren's syndrome [23,24 & ].
In the last decades, animal models clarified the role of inflammatory cells and mediators, their interactions with the target tissue and autonomic nervous system, effects of the environment, oxidative stress and aging [18, [25] [26] [27] . They also have being elucidative to the potential of novel treatments with biological, stem cells and gene therapy [28] [29] [30] .
In-vivo confocal microscopy has been a new tool among the clinical instruments that is able to identify inflammatory cells, goblet cells and nerve fiber density in vivo [31] . Evaluation of conjunctival cells obtained by impression cytology has been used to evaluate expression of HLA-DR by flow cytometry, investigation of cytokines by real-time PCR and oxidative stress in Sjögren's syndrome patients [31] [32] [33] [34] . A study showed that aqueous tear-deficient patients (irrespective of Sjögren's syndrome or non-Sjögren's syndrome status) had the greatest interleukin-17, interferon (IFN)-g and lower MUC5AC mRNA transcripts compared with control subjects [35 & ]. Another recent study clearly showed that 0.1% dexamethasone eye drops blunted the acute adverse effects of an experimental periocular low humidity challenge [36 & ].
HISTORY
In his initial publications regarding keratoconjunctivitis sicca, Dr Henrik Sjögren described 19 women with dry eye; some of whom also had salivary gland dryness and inflammatory infiltrates including salivary gland and other organ dryness and inflammatory infiltrates [37, 38] . It took three decades for the disease be relabeled as Sjögren's syndrome and more than 20 years to an autoimmune mechanisms be attributed to Sjögren's syndrome [39] . Those concepts paved the diagnostic criteria and opened up the opportunities for studies in animal models [40] .
The first attempts to induce Sjögren's syndrome in animal models were made with chronic use of hydralazine, isoniazid and procainamide among other drugs. Both hydralazine and isoniazid, given for 6 months, independently, induced the expression of antinuclear factor (AFN), more frequently in C57BL/ 6 than in BALB/c mice; more frequently in females than in males and in aged mice. These observations were not reverted in most of them after drug discontinuation [41] . Although no other parameters regarding Sjögren's syndrome were reported for this or other drugs in animal models, there are clinical reports of Sjögren's syndrome induced by chronic hydralazine and other drugs in humans that reverted after the drug discontinuation [42, 43] . The mechanism that lead those drugs to trigger autoimmunity and Sjögren's syndrome is suggested to include DNA methylation and histone modification influencing gene regulation [44] .
In the 1970s, the use of spontaneous animal models of autoimmunity took the place of the drug-induced Sjögren's syndrome in the bench and these models were deeply investigated. In the
KEY POINTS
Clinical assessment for early diagnosis of Sjögren's syndrome in dry eye patients may help to prevent irreversible complications.
Advances in Sjögren's syndrome dry eye diagnosis involve confocal microscopy and conjunctiva impression cytology markers.
Ocular manifestations are frequent findings in spontaneous autoimmune models of Sjögren's syndrome.
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Th1, Th17 [10] [11] [12] Th1, Th17 Th1 [8] , Th2 [13] ; Th17 [8] Youngest 1990s, mice strains submitted to gene knockout replaced the spontaneous models. In recent years, despite great availability of different models, the animal models that combine environmental, drug and/or genetic interventions have been preferably used to investigate the pathogenesis of Sjogren's syndrome [45, 46] .
SPONTANEOUS ANIMAL MODELS OF SJÖ GREN'S SYNDROME
During the 1970s and 1990s, two rodent models more frequently used were NZB/w 1 and MRL/lpr strains. Other emerging models are nonobese diabetic strain (NOD), C57BL/6.NOD-Aec1Aec2, CD25KO and thrombospondin-1 (TSP-1) KO mice. Frequent endpoints in animal models are: salivary flow, presence of autoantibodies in serum, systemic cytokine expression and within the glands, and, histopathology and focus score. Specific ocular manifestations that have been evaluated and are relevant for the human disease include: tear volume, tear protein concentrations, increased uptake of fluorescent dyes (to measure corneal barrier function), number of mucin-filled goblet cells and CD4 þ T cell infiltration in conjunctiva.
Nzb/W F1
The first generation of inbred New Zealand Black mice (NZB) crossed with New Zealand White mice (NZW) developed autoimmunity characterized by B lymphocyte hyperreactivity and autoantibodies production. NZB/W F1 also shows lymphocytic infiltration of the lacrimal and salivary glands, initially with a foci pattern, that progresses with destruction of the acinar structures and sicca syndrome. The disease starts by the age of 6 months, and it is more aggressive in females. It can be worsened with aging and by inflammatory challenge with Freund's incomplete adjuvant [47] [48] [49] [50] .
No corneal or other ocular surface changes were observed along the disease progression [16] . Female mice die in general by the age of 9 months because of autoimmune disease and males live to around 1 year [51] .
MRL/lpr
MRL/lpr mice develop autoimmune disease comparable with Sjögren's syndrome, owing to a spontaneous deletion in the gene lpr, responsible for coding the proapoptotic protein Fas, a member of the tumor necrosis factor-a receptor family. The absence of Fas induces proliferation of lymphocytes, in target organs, including lacrimal and salivary glands; with markedly positive CD4 þ T helper (Th) cells, among other cells. There is also infiltration of choroidal and scleral tissues. The infiltrates have a focal distribution and usually surround small arterioles, similar to necrotizing vasculitis. The disease progresses from the first to the fifth month of age. It achieves a rate of 67% by 6 months, and is more frequent in females, and commonly the death occurs by 6 months of age with glomerulonephritis, arthritis and vasculitis [51] . These MRL/lpr mice also develop circulating autoantibodies, such as anti-Ro and anti-Sm [52, 53] ; however, it does not affect 100% of the mice, suggesting the role of an environmental trigger [54] .
Despite of its massive lacrimal gland lymphocytic infiltration, these animals do not develop secretory dysfunction or corneal damage measured by fluorescein staining [55] .
The genetic background of the lpr mutation seems to determine the extension and pattern of inflammation. BALB/c mice are Th-2 prone, whereas C57BL/6 (B6) mice are Th-1 skewed. MRL/lpr mice on a BALB/c background have greater lymphocytic infiltration in the lacrimal gland than C57BL/6 mice carrying the same mutation (B6.Lpr) [49] . Compared with wild-type mice, MRL/lpr mice have increased numbers of filled goblet cells, [56] probably due to a high protective interleukin-13 environment [57] . B6. Lpr mice have increased lymphocytic infiltration in the lacrimal gland at 8 and 12 weeks of age compared with wild-type mice (Fig. 1) , increased CD4 infiltration in the conjunctiva and lower goblet cell density (Fig. 1) , whereas there is no change in corneal barrier function (data not shown). Although both strains developed dacryoadenitis, albeit not at the same level of severity, the opposing findings regarding goblet cell density highlight the importance of genetic background in some of these spontaneous models of Sjögren's syndrome.
Nonobese diabetic strain
The NOD mouse is a spontaneous mouse model of autoimmune disease, used to study diabetes mellitus type 1 and Sjögren's syndrome. It was induced by hyperglycemic brother and sister mice inbreeding for more than 20 generations [58] .
The disease onset occurs by the 4 th week of life with lymphocytic infiltration of the target tissues, and it is present in about 95% of the mice by 30 weeks of age [59] . The manifestations have a sexrelated incidence and are regulated by sex hormones [60] . About 80% of female and less than 20% of male become diabetic, the sialoadenitis followed the same pattern; however, the dacryoadenitis is biased toward male mice [49, 61, 62] . In addition, the disease may be influenced by housing conditions and intestine microbiota [45] .
The salivary flow rate and the relative protein concentration in saliva are reduced in comparison with control mice [63] . Tear secretion, conjunctival goblet cells and lymphocytic infiltration are changed in comparison with the C57BL/6 strain [64] . Nevertheless, the ocular surface and cornea integrity seem not to be affected by the disease [17] .
C57BL/6.NOD-Aec1Aec2
The C57BL/6.NOD-Aec1Aec2 (Aec) mouse model was created by transferring genes located within the 2 chromosomal intervals Idd3 and Idd5 from parenteral NOD into nonsusceptible C57BL/6 mice [4] . The manifestations are age-dependent and both submandibular and lacrimal glands are involved. These mice have antinuclear and antimuscarinic 3 receptor antibodies [4] . The disease in Aec mice has three distinct phases with definite lymphocytic infiltration and loss of salivary flow at 20 weeks of age [65] .
We have recently characterized the ocular manifestations of female Aec mice and observed decreased numbers of filled conjunctival goblet cells as soon as 12 weeks of age, which was accompanied by an increase in infiltrating CD4 þ T cells in conjunctiva and increased expression of IFN-g and interleukin-17 in cornea and conjunctiva [14 & ]. There was mild lymphocytic infiltration in the lacrimal gland (the infiltration was a mix of Th-1 and Th-17 cells, CD8 and B cells) and a paradox increase in tear volume. The ratio of IgA (normally produced by lacrimal glands) to IgG and IgM (plasma immunoglobulins) increased with aging from 4 to 20 weeks in wild-type mice whereas it did not change in Aec mice, indicating that ocular changes occurred independently of tear volume changes.
CD25KO
IL-2 signals through a heterodimeric receptor compost of three chains. The alpha chain (also known as CD25) is the binding portion of the receptor. CD25KO mice have no regulatory T cells and the activated T cells escape control of activationinduced T cell death, becoming autoreactive [66] . These mice develop lymphocytic infiltration of several organs, notably salivary and lacrimal glands and colon [67] . The dacryoadenitis is very severe, develops rapidly and it is age-dependent [68] . Mice start to have lacrimal gland infiltration around 4 weeks of age [15] and complete lacrimal gland disorganization and atrophy is observed around 12-16 weeks [7] . There is no sex predilection in this model [68] , and antimuscarinic receptor antibodies can be found in the sera [7] . There is a marked inflammation at the conjunctiva of CD25KO mice and corneal barrier disruption at 12 weeks of age, which paralleled the increase of interleukin-17A mRNA transcripts in cornea epithelia [18] , T cell infiltration and loss of goblet cells (Fig. 2) . Deletion of interferon-g delayed dacryoadenitis temporally and improved the severity of lacrimal gland infiltration [7] , whereas rescued the number of filled goblet cells (Fig. 2) , implicating a pathogenic role for Th-1 þ cells.
TSP-1KO
TSP-1 is a physiological activator of TGF-b and it is expressed in both dendritic cells and ocular surface epithelia [69] . TSP-1KO mice develop Sjögren's syndrome-like disease with aging, inclusive of anti-Sjögren's syndrome and anti-Sjögren's syndrome antibodies, progressive dacryoadenitis, conjunctival inflammation and loss of filled goblet cells [8, 13] . They also develop increased corneal fluorescein staining [8] . The disease phenotype is first observed around 12 weeks of age and worsening of dacryoadenitis and inflammatory cytokines are seen around 48 weeks of age. Similar to another transgenic mouse in which TGF-b signaling is disrupted in CD4 þ T cells [69] , TSP-1KO mice show resistance to desiccation-induced dry eye [70] . These results indicate a strong environmental component in disease induction.
INDUCIBLE SJÖ GREN'S SYNDROME ANIMAL MODELS
There are many inducible Sjögren's syndrome animal models. A short and noncomprehensive list includes preganglionic parasympathetic denervation [71] , administration of benzalkonium eye drops [72, 73] , injection of adenoviral vectors into salivary gland [74] , injection of interleukin-1 [75] or activated CD4 þ T cells into lacrimal glands or into immunodeficient mice [76] [77] [78] [79] , injection of botulinum toxin A into lacrimal glands [80] and pharmacological blockade of lacrimal gland secretion combined with environmental stress [81] [82] [83] [84] [85] [86] . Interestingly, these inducible models tend to represent acute changes and many of them have marked corneal barrier disruption, with significantly increased permeability to fluorescent dyes, the hallmark of dry eye disease. Also of note, maintenance of stimulus and prolonged dryness leads to corneal metaplasia and increased expression of skin-like small proline-rich proteins, which are impermeable to dyes [83, 84, 87] . Therefore, it is plausible to speculate that lack of corneal staining in some of the spontaneous rodent models may not be an indication of lack of corneal dysfunction, but rather an indication of corneal metaplasia that warrants further investigation.
CONCLUSION
Several Sjögren's syndrome dry eye models in a variety of species have been developed to improve the understanding of the disease. Here we described the correlations between mice models and clinical and laboratorial aspects of Sjögren's syndrome. The weakness of those models to the broad understanding of the disease is the lack of one or more features of the disease. The strength is the fact that the starting point, time-course of the signs and the dose-response of the interventions are well controlled. Pathologic and therapeutic aspects of Sjögren's syndrome have benefited from those experimental models. Take-home messages are: in the clinic, most of the patients arrive with incomplete features of Sjögren's syndrome, mostly with symptoms of dry eye; therefore, it is mandatory to investigate Sjögren's syndrome, prior to the irreversible complications appear; an animal model that carries association of glandular and extraglandular manifestations helps to understand the mechanisms of Sjögren's syndrome, and the initial manifestations of the disease and response to therapy.
